Summary

Patients that received customized lung cancer treatment based on their levels of BRCA1 and RAP80 did not experience an improvement in progression-free survival or overall survival (OS), compared with standard cisplatin plus docetaxel. This article presents data from the Multicenter, Predictive, Prospective, Phase 3, Open, Randomized Pharmacogenomic Study in Patients With Advanced Lung Carcinoma study [BREC; NCT00617656; Moran T et al. J Clin Oncol 2013 (suppl; abstr LBA8002)].